Dixit S N, Behari M, Ahuja G K
Department of Neurology, All India Institute of Medical Sciences, New Delhi.
J Assoc Physicians India. 1999 Aug;47(8):784-6.
Selegiline hydrochloride, a selective MAO-B inhibitor is known to improve motor functions in Parkinson's disease (PD). The present study was undertaken to study the effect of selegiline on memory and intelligence of PD patients.
Thirty two patients of PD were divided in two groups: selegiline group (n = 17) received 10 mg selegiline per day and control group (n = 15) did not receive selegiline. Patients receiving trihexyphenidyl and selegiline were excluded. All other treatment remained unchanged. All patients were examined at baseline and after three months for change in UPDRS score, WAIS score, memory test and P300.
Patients in selegiline group had less severe disease (UPDRS score 24.11 +/- 14.07) as compared to controls (UPDRS score 40.53 +/- 18.52). There was significant improvement in UPDRS score (p < 0.05), WAIS (p < 0.001) and memory (p < 0.001) in selegiline group. In the control group there was a significant prolongation of P300 latency (p < 0.05).
The study suggests that selegiline improves memory functions and intelligence in PD patients in addition to motor functions. It also prevents prolongation of P300 latency which is a marker of cognitive function.
盐酸司来吉兰是一种选择性单胺氧化酶-B抑制剂，已知其可改善帕金森病（PD）患者的运动功能。本研究旨在探讨司来吉兰对PD患者记忆力和智力的影响。
32例PD患者分为两组：司来吉兰组（n = 17），每天服用10mg司来吉兰；对照组（n = 15），不服用司来吉兰。排除同时服用苯海索和司来吉兰的患者。所有其他治疗保持不变。所有患者在基线时及三个月后接受检查，评估统一帕金森病评定量表（UPDRS）评分、韦氏成人智力量表（WAIS）评分、记忆测试及P300的变化。
与对照组（UPDRS评分为40.53±18.52）相比，司来吉兰组患者的病情较轻（UPDRS评分为24.11±14.07）。司来吉兰组的UPDRS评分（p < 0.05）、WAIS评分（p < 0.001）和记忆力（p < 0.001）均有显著改善。在对照组中，P300潜伏期显著延长（p < 0.05）。
该研究表明，司来吉兰除了改善PD患者的运动功能外，还能改善其记忆功能和智力。它还可防止P300潜伏期延长，而P300潜伏期是认知功能的一个指标。
